Senior Manager / Associate Director, HCP NPP Omnichannel Marketing at Immunome, Inc. | Bothell, WA | $190K/yr – $230K/yr

Immunome, Inc.

Senior Manager / Associate Director, HCP NPP Omnichannel Marketing

Bothell, WA (On-site)

$190K/yr – $230K/yrSenior Level5+ years expFull time

Posted 4 months ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Drive end-to-end HCP digital, omnichannel campaigns and AI-enabled marketing at Immunome, focusing on oncology and NPP regulatory-compliant education and activation.

Must-have: 5+ years in pharmaceutical or healthcare digital marketing with omnichannel strategy
Standout: AI-driven marketing capabilities adoption and data-enabled personalization

Job Description

Responsibilities

Develop and execute data-driven HCP digital campaigns, content, and modular journeys based on time to diagnosis, specialty, prescribing behavior, and real-time engagement signals to drive disease education and product adoption
Manage marketing automation platforms and digital engagement tools to enable personalized HCP communication
Monitor and analyze campaign performance and engagement metrics to continuously refine targeting, creative assets, and channel mix
Partner with media agencies to develop and optimize channel strategy, media planning and activation, ensuring precise audience targeting and efficient budget allocation
Lead the development and execution of the HCP non-personal promotion and omnichannel engagement strategy
Design customer journeys that coordinate field promotion, digital engagement, and non-personal channels to deliver a cohesive HCP experience
Design and implement an integrated digital ecosystem (e.g., websites, search, social, CRM, programmatic media, and paid search) that supports education, activation, and sustained engagement
Champion the adoption of AI-driven marketing capabilities, including predictive analytics, machine learning models, and automated decisioning engines to enhance targeting, personalization, and campaign performance
Leverage AI and advanced analytics to enable next-best-action/next-best-message frameworks, dynamic content personalization, and real-time optimization of HCP engagement
Partner with analytics and technology teams to pilot and scale new AI-enabled marketing solutions while ensuring compliance with regulatory and data governance standards

Requirements

Bachelor’s degree required; Advanced degree (e.g., PharmD, MBA) preferred
5+ years of experience in pharmaceutical, biotech, or healthcare marketing, with a strong focus on digital, NPP, and omnichannel strategy
Oncology launch experience required
Proven success in digital HCP marketing (web, social, SEO/SEM, CRM, and paid media strategy) and in media planning and execution
Strong understanding of MLR/PRC processes, claims substantiation, and OPDP regulations.
Demonstrated ability to thrive in a fast-paced biotech environment
Ability to travel ≥20%, including occasional weekends
HCP digital and NPP expertise: Deep understanding of HCP digital engagement tactics and how to integrate channels into cohesive omnichannel journeys
Strong analytical and problem-solving skills, with the ability to leverage market research and performance data to inform decisions and optimize impact
Strong project management and operational execution skills; able to manage multiple workstreams and launch-critical deadlines in a fast-paced environment
Excellent communication, storytelling, and presentation skills—able to simplify complex clinical information for varied audiences
Experience managing agencies/vendors, budgets, and complex project plans with strong operational rigor and attention to detail

Preferred

Advanced degree (e.g., PharmD, MBA) preferred

Immunome, Inc.

2.5 Glassdoor

Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Our most advanced pipeline programs are varegacestat (formerly AL102), a gamma secretase inhibitor which is currently in a Phase 3 trial for treatment of desmoid tumors; IM-1021, a ROR1-targeted ADC which is currently in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand, which recently received IND clearance. Our pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors.

Founded in 2008

Bothell, Washington, USA

187 employees (3 in marketing)

www.immunome.com

58% recommend to a friend